Scholarlink

Background <p>Fabry disease (FD) is an X-linked lysosomal storage disorder characterized by cellular accumulation of globotriaosylceramide (Gb3).</p> Methods <p>We investigated dermal Gb3 load as a potential surrogate marker for systemic FD manifestations by applying an automated image analysis pipeline to skin punch biopsies from the lower leg of 149 individuals carrying variants in <i>GLA</i>, the gene encoding alpha-galactosidase A. Variants were stratified by pathogenicity: Group 1 (pathogenic), Group 2 (non-pathogenic), and Group 3 (variants of unknown significance). Gb3 was visualized via Shiga toxin subunit B and quantified using CellProfiler (v4.1.3). Results were compared to healthy controls and patients with idiopathic small fiber neuropathy.</p> Results <p>Dermal Gb3 load was elevated in both men and women with pathogenic <i>GLA</i> variants (Group 1, <i>p</i> &lt; 0.001), excluding those with the N215S variant. Increased Gb3 deposition was associated with pain in men (<i>p</i> &lt; 0.05), but not with overall disease severity, treatment status, or cerebral white matter lesions. Diagnostic sensitivity and specificity to correctly determine FD were 67% and 95% in men, and 78% and 81% in women, respectively.</p> Conclusion <p>Our findings demonstrate the feasibility of automated dermal Gb3 quantification and its capacity to detect cutaneous Gb3 accumulation in pathogenic <i>GLA</i> variant carriers. However, its diagnostic accuracy is moderate, and it does not reliably reflect systemic involvement in FD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Automated quantification of skin Gb3 load and white matter lesion assessment in Fabry disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Catharina Pfister,
  • Magnus Schindehütte,
  • Christoph Erbacher,
  • Thomas Klein,
  • Simone Rost,
  • Aljosha Calvin Lang,
  • Mirko Pham,
  • Peter Nordbeck,
  • Christoph Wanner,
  • Claudia Sommer,
  • Nurcan Üçeyler

摘要

Background

Fabry disease (FD) is an X-linked lysosomal storage disorder characterized by cellular accumulation of globotriaosylceramide (Gb3).

Methods

We investigated dermal Gb3 load as a potential surrogate marker for systemic FD manifestations by applying an automated image analysis pipeline to skin punch biopsies from the lower leg of 149 individuals carrying variants in GLA, the gene encoding alpha-galactosidase A. Variants were stratified by pathogenicity: Group 1 (pathogenic), Group 2 (non-pathogenic), and Group 3 (variants of unknown significance). Gb3 was visualized via Shiga toxin subunit B and quantified using CellProfiler (v4.1.3). Results were compared to healthy controls and patients with idiopathic small fiber neuropathy.

Results

Dermal Gb3 load was elevated in both men and women with pathogenic GLA variants (Group 1, p < 0.001), excluding those with the N215S variant. Increased Gb3 deposition was associated with pain in men (p < 0.05), but not with overall disease severity, treatment status, or cerebral white matter lesions. Diagnostic sensitivity and specificity to correctly determine FD were 67% and 95% in men, and 78% and 81% in women, respectively.

Conclusion

Our findings demonstrate the feasibility of automated dermal Gb3 quantification and its capacity to detect cutaneous Gb3 accumulation in pathogenic GLA variant carriers. However, its diagnostic accuracy is moderate, and it does not reliably reflect systemic involvement in FD.